Susan Desmond-Hellmann - The 25 most influential people in biopharma today

A tough leader with a nice touch

Susan Desmond-Hellmann
Chancellor
University of California, San Francisco

At Genentech, Susan Desmond-Hellmann supervised one of the hottest streaks in drug development history. Left independently wealthy when she resigned after the big Roche takeover, Desmond-Hellman put a rich retirement on hold and pursued a new career as chancellor of the University of California, San Francisco, where she has been molding a drug development hub by the Bay with help from industry heavyweights like Sanofi ($SNY) and Pfizer ($PFE).

This time, she's relying on top investigators at the university to help mold a new style of early R&D efforts. At a time Big Pharma wants to reorganize discovery efforts around leading campuses, UCSF has been busily hatching a string of new academic pacts. And she's been doing it all with a sunny disposition, remaining cheerful even during some high-wire restructuring efforts at the university.

"She's a very nice person, so this did not come naturally to her," Arthur Levinson, the legendary ex-CEO of Genentech, recently told The New York Times. "She became a tough leader, tough in a positive sense. She was willing to make tough calls without much difficulty."

By putting herself at the head of one of the biggest trends in research, Desmond-Hellmann will inevitably help craft a template for academic/corporate partnerships that others will follow. Long-term success would also help provide a new and important source of research funding at a time federal subsidies are flagging.

Susan Desmond-Hellmann - The 25 most influential people in biopharma today
Read more on

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.